Multiplex opsonophagocytosis assay (MOPA): a useful tool for the monitoring of the 7-valent pneumococcal conjugate vaccine

Vaccine
D BogaertP W M Hermans

Abstract

Pneumococcal conjugate vaccination is highly efficacious against invasive diseases in young children. Since host protection is mainly mediated by opsonin-dependent phagocytosis, the in vitro measurement of opsonophagocytic activity of the anti-capsular antibodies is assumed to be a reliable correlate of protection to monitor vaccine efficacy. Unfortunately, the methods used so far are all tedious to perform and material-consuming. Therefore, we modified the multi-specificity opsonophagocytosis killing assay (MSOPKA) into a high-throughput method, which simultaneously measures the opsonophagocytosis against the seven serotypes covered by the current conjugate vaccine in a single assay. In the so-called multiplex opsonophagocytosis assay (MOPA), a mixture containing equal numbers of colony forming units (CFUs) of chloramphenicol-resistant serotype 4, spectinomycin-resistant serotype 6B, streptomycin-resistant serotype 9V, erythromycin-resistant serotype 14, rifampicin-resistant serotype 18C, tetracycline-resistant serotype 19F, and trimethoprim-resistant serotype 23F pneumococci was used as a target mixture and incubated with serial dilutions of test serum. After opsonophagocytosis by differentiated HL-60 cells in the presence of...Continue Reading

Citations

Jun 18, 2009·Current Opinion in Pulmonary Medicine·Jay B VarkeyBasil Varkey
Jun 24, 2015·Journal of Immunology Research·Shu Ki TsoiAndrew C Steer
May 10, 2013·Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy·Joon Young SongMoon H Nahm
Jul 16, 2014·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Yu-Lin HuangJodi B Segal
Jan 17, 2017·Journal of cardiovascular ultrasound·Maaike AlkemaChristian Loewe
Feb 16, 2007·Clinical and Vaccine Immunology : CVI·Kevin FabrizioLiise-anne Pirofski
Sep 9, 2006·Clinical and Vaccine Immunology : CVI·Robert L Burton, Moon H Nahm
Feb 10, 2006·Clinical and Vaccine Immunology : CVI·Sandra Romero-SteinerMoon H Nahm
Jan 12, 2005·Clinical and Diagnostic Laboratory Immunology·R A FleckM H Nahm
Oct 8, 2005·Clinical and Diagnostic Laboratory Immunology·Kathryn T BiegingSandra Romero-Steiner
Jun 7, 2018·Nature Reviews. Immunology·Hao Li, Babak Javid

❮ Previous
Next ❯

Related Concepts

Related Feeds

Bacterial Pneumonia (ASM)

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Bacterial Pneumonia

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Related Papers

The Journal of Infectious Diseases
Tamara PilishviliActive Bacterial Core Surveillance/Emerging Infections Program Network
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
M S DworkinAdult and Adolescent Spectrum of HIV Disease Project
© 2021 Meta ULC. All rights reserved